Decitabine: all 314 studies that test it
Page 2 of 4. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT02003573Phase 1Results posted
- Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT01893320Phase 1/2Results posted
- A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01853228Phase 1/2Results posted
- Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT01846624Phase 2Results posted
- Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01829503Phase 2Results posted
- Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell TransplantCompletedNCT01812252Phase 2Results posted
- Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute LeukemiaCompletedNCT01794702Phase 1/2Results posted
- Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)CompletedNCT01786343Phase 2Results posted
- Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT01729845Phase 1/2Results posted
- Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskCompletedNCT01720225Phase 2Results posted
- Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01707004Phase 2Results posted
- Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
- Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSTerminatedNCT01607645Phase 2Results posted
- Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic SyndromesCompletedNCT01593670Phase 2Results posted
- A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01546038Phase 2Results posted
- An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
- A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALLTerminatedNCT01483690Phase 1/2Results posted
- Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT01378416Phase 1Results posted
- Decitabine for High-Risk Sickle Cell DiseaseCompletedNCT01375608Phase 2Results posted
- Re-expression of ER in Triple Negative Breast CancersTerminatedNCT01194908Phase 1/2Results posted
- Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsTerminatedNCT01177540Phase 2Results posted
- Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic SyndromeCompletedNCT01165996Phase 1/2Results posted
- To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.TerminatedNCT01011283Phase 4Results posted
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
- Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and PanobinostatTerminatedNCT00925132Phase 1/2Results posted
- Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00882206Phase 2Results posted
- Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
- A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic SyndromeCompletedNCT00796003Phase 1Results posted
- Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00778375Phase 2Results posted
- Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00760084Phase 2Results posted
- An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)CompletedNCT00744757Phase 2Results posted
- Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic MelanomaCompletedNCT00715793Phase 1/2Results posted
- LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
- Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia IntermediaCompletedNCT00661726Phase 2Results posted
- Low-Dose Decitabine in Treating Patients With Symptomatic MyelofibrosisTerminatedNCT00630994Phase 2Results posted
- Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic SyndromeCompletedNCT00621023Phase 2Results posted
- A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)CompletedNCT00619099Phase 2Results posted
- Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell CarcinomaTerminatedNCT00561912Phase 2Results posted
- Decitabine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00492401Phase 2Results posted
- Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)CompletedNCT00479232Phase 1Results posted
- Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian CancerCompletedNCT00477386Phase 1/2Results posted
- Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00416598Phase 2Results posted
- Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)CompletedNCT00398983Phase 2/3Results posted
- Decitabine and Tretinoin in Treating Patients With Myelodysplastic SyndromesCompletedNCT00382200Phase 1/2Results posted
- Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)CompletedNCT00358644Phase 2Results posted
- A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic SyndromesCompletedNCT00260065Phase 2Results posted
- Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
- Decitabine in Treating Patients With MyelofibrosisActive, not recruitingNCT00095784Phase 2Results posted
- Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131CompletedNCT00085293Phase 2Results posted
- Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
- Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT07216833Phase 1
- Pilot Study of Reduced Venetoclax ExposureActive, not recruitingNCT07163793Phase 2
- Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT06941688Phase 2
- Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched DonorWithdrawnNCT06572631Phase 1
- A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasWithdrawnNCT06474663Phase 1
- PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic SyndromesActive, not recruitingNCT06091267Phase 1/2
- A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
- To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy MalesCompletedNCT05816356Phase 1
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesActive, not recruitingNCT05796570Phase 2
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesWithdrawnNCT05740449Phase 1/2
- Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05638984Phase 2
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1
- Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
- tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancErTerminatedNCT05360264Phase 2
- Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT05265962Phase 2
- Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxActive, not recruitingNCT05222984Phase 1
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruitingNCT05038592Phase 1/2
- A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesWithdrawnNCT04985656Phase 2
- Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic AnemiaTerminatedNCT04854889Phase 2
- Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
- Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor BurdenStatus unknownNCT04553393Phase 1/2
- Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
- Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
- Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTActive, not recruitingNCT04476199Phase 2
- Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaStatus unknownNCT04353479Phase 2
- Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
- Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04279379Phase 2
- Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late SalvageTerminatedNCT04252248Phase 1
- Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
- Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCTStatus unknownNCT04123392Phase 2/3
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)TerminatedNCT04113616Phase 1/2
- Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCTStatus unknownNCT04098653Phase 2/3
- Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult SubjectsCompletedNCT04086238Phase 1
- Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
- Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell CarcinomaStatus unknownNCT04049344Phase 2
- Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
- Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid TumorsActive, not recruitingNCT03875287Phase 1
- Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDSStatus unknownNCT03855371Phase 1
- Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid LeukemiaActive, not recruitingNCT03844815Phase 1
- Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy SubjectsCompletedNCT03828084Phase 1
- Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerWithdrawnNCT03709550Phase 1/2
- Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell TransplantationCompletedNCT03663751Phase 2
- Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCTStatus unknownNCT03596892Phase 2/3
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT03579082Phase 4
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic LymphomaStatus unknownNCT03558412Phase 4
- Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaStatus unknownNCT03553537Phase 3
- Safety and Efficacy Evaluation of Decitabine With R-GDPStatus unknownNCT03535753Phase 1
- Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
- Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.Status unknownNCT03467178Phase 2